Ocular Therapeutix, Inc. (OCUL)
Company Description
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology.
The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease.
The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD).
Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
| Country | United States |
| Founded | 2006 |
| IPO Date | Jul 25, 2014 |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Employees | 228 |
| CEO | Antony Mattessich |
Contact Details
Address:
24 Crosby Dr Bedford, Massachusetts 01730-1402 United States | |
| Phone | 781 357 4000 |
| Website | ocutx.com |
Stock Details
| Ticker Symbol | OCUL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| CIK Code | 0001393434 |
| CUSIP Number | 67576A100 |
| ISIN Number | US67576A1007 |
| Employer ID | 20-5560161 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Antony Mattessich | President, Chief Executive Officer and Director |
| Donald Notman Jr. | Chief Financial Officer |
| Dr. Michael H. Goldstein M.B.A., M.D., M.M. | President of Ophthalmology and Chief Medical Officer |
| Dr. Peter K. Jarrett Ph.D. | Chief Scientific Officer |
| Philip C. Strassburger | General Counsel |
| William H. Ransone II | Vice President of Global Sales and Marketing |
| Tracy Smith | Vice President of Human Resources |
| Scott Corning | Senior Vice President of Commercial |
| Christopher G. White | Chief Business Officer |
| Dr. Rabia Gurses Ozden M.D. | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 21, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 21, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 21, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 21, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 21, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 21, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 17, 2022 | 8-K | Current report |
| Jun 8, 2022 | 8-K | Current report |
| May 16, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| May 16, 2022 | 4 | Statement of changes in beneficial ownership of securities |